Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2012: Volume 17/ Issue 46 Article 1
Back to Table of Contents
Download (pdf)
Next

Eurosurveillance, Volume 17, Issue 46, 15 November 2012
Editorial
Fifth European Antibiotic Awareness Day on 18 November - joining forces to reduce antibiotic resistance
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Eurosurveillance editorial team. Fifth European Antibiotic Awareness Day on 18 November - joining forces to reduce antibiotic resistance. Euro Surveill. 2012;17(46):pii=20314. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20314

Antibiotics are medicines that are beneficial for mankind and their use in treatment and prevention of bacterial diseases has greatly contributed to reducing the overall burden of such infections. However, already since antibiotics have been used in clinical practice, emergence and spread of antibiotic resistance has represented an obstacle for the effective treatment of infected patients. A growing number of resistance mechanisms and antibiotic-resistant strains have been described and related infections have been increasing in numbers. These trends have been identified as a threat and have thus been watched closely by scientists and public health experts globally to have a clear picture of the magnitude of the problem and its impact on public health, and to identify and implement appropriate control measures.
Extensive coverage in the scientific and general literature illustrates the importance of antibiotic resistance in research and public health practice. On 14 November 2012, entering the simple term ’antibiotic resistance’ in PubMed and Google Scholar resulted in the retrieval of 133,163 and over 1,300,000 related publications, respectively. Antibiotic resistance limits the number of options for effective treatment of infected patients. In extreme cases such as infections with carbapenemase-producing Enterobacteriaceae, alternatives for treatment are limited to only few antibiotics that often are old, have side-effects and limitations for their use.

Antibiotic-resistant bacteria are often responsible for healthcare-associated infections. This is obviously related to antibiotic prescribing practices in hospitals and other healthcare settings, and to poor compliance with infection control measures to prevent spread and patient-to-patient transmission of these bacteria. In this week’s issue, Eurosurveillance publishes an article by Zarb et al. in which the authors present the results from a pilot study using a new point prevalence protocol for healthcare-associated infections and antimicrobial use in European acute care hospitals. The results from participating hospitals in 23 countries show that 7.1% of patients had a healthcare-associated infection, and 34.6% received at least one antimicrobial agent [1].

Healthcare-associated infections and antibiotic resistance are closely related issues that concern patients, physicians, healthcare providers and public health experts. Due to their associated morbidity and mortality, they lead to a high strain on individuals and health systems. For example it is estimated that in the European Union (EU) alone, the excess hospital stay attributable to selected common multidrug-resistant infections in hospitals amounts to 2.5 million days and 25,000 patients die each year as a result of these infections [2].

Acknowledging the importance of the subject, the EU Commission formulated a strategy against Antimicrobial Resistance and EU Health Ministers adopted Council recommendations on the prudent use of antimicrobial agents in human medicine already in 2001 [3,4] and many more initiatives followed. Last year, the European Commission released its Action plan against the rising threats from antimicrobial resistance [5]. Another initiative is the European Antibiotic Awareness Day (EAAD) that provides a platform and support for national campaigns on the prudent use of antibiotics [6]. This European health initiative, coordinated by the European Centre for Disease Prevention and Control (ECDC) in Stockholm, has grown over the years and new important partners have joined. The first EAAD took place on 18 November 2008 and has been marked at the same date also in the following years. While the first year saw 32 countries participating, in 2012, over 40 countries have started or will launch activities around 18 November when the fifth EAAD takes place. Moreover, in 2012, the World Health Organization Regional Office for Europe supports the campaign actively for the first time and a range of activities have also been organised this week in the United States, in Canada and in Australia [7-9].

In the run up of the day, and in previous years much activity has been ongoing in mass and social media that should have resulted in increasing awareness of the problem of antibiotic resistance and the need to use antibiotics prudently, i.e. only when indicated, among the general public and among health professionals.

An initial evaluation of EAAD took place in 2009, showing strong political and stakeholder support [10], however, in a next step it will be important to measure the success of the initiative and see whether awareness has been transformed into action. Such action could be indicated for example by more adequate prescribing by doctors and less self-medication by patients, and as a result less antibiotic consumption. Obtaining the respective data and attributing them to efforts associated with the EAAD as one important element in the fight against antibiotic resistance is a challenge. Visible results can only be expected over time and evaluation may require specific studies and analyses. Eurosurveillance will keep on following the evolution of the EAAD and publish articles that contribute to give insight into the situation and related issues connected with antimicrobial resistance and healthcare-associated infections.



References

  1. Zarb P, Coignard B, Griskeviciene J, Muller A, Vankerckhoven V, Weist K, et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012;17(46):pii=20316. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20316
  2. European Centre for Disease Prevention and Control (ECDC) / European Medicines Agency (EMEA). Joint Technical Report. The bacterial challenge: time to react. Stockholm: ECDC; Sep 2009. Available from: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf
  3. European Commission. Communication from the Commission of 20 June 2001 on a Community strategy against antimicrobial resistance. [Accessed 15 Nov 2012]. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52001DC0333:EN:HTML
  4. Council of the European Union. Council Recommendation of 15 November 2001 on the prudent use of antimicrobial agents in human medicine (2002/77/EC). Official Journal of the European Communities, 2002 Feb. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2002:034:0013:0016:EN:PDF
  5. European Commission. Communication from the Commission to the European Parliament and the Council. Action plan against the rising threats from Antimicrobial Resistance. COM (2011) 748. Available from: http://ec.europa.eu/dgs/health_consumer/docs/communication_amr_2011_748_en.pdf
  6. European Centre for Disease Prevention and Control (ECDC) European Antibiotic Awareness Day (EAAD). Stockholm: ECDC. [Accessed 15 Nov 2012]. Available from: http://ecdc.europa.eu/en/eaad/Pages/Home.aspx
  7. Centers for Disease Control and Prevention (CDC). Get Smart About Antibiotics Week. Atlanta: CDC. [Accessed 15 Nov 2012]. Available from: http://www.cdc.gov/getsmart/index.html
  8. AntibioticAwareness.ca [Internet]. Antibiotic Awareness Week. [Accessed 15 Nov 2012]. Available from: http://antibioticawareness.ca/
  9. NPS Medicinewise [Internet]. Antibiotic Awareness Week. [Accessed 15 Nov 2012]. Available from: http://www.nps.org.au/bemedicinewise/antibiotic_resistance/antibiotic_awareness_week
  10. Earnshaw S, Monnet DL, Duncan B, O’Toole J, Ekdahl K, Goossens H, et al. European Antibiotic Awareness Day, 2008 – the first Europe-wide public information campaign on prudent antibiotic use: methods and survey of activities in participating countries. Euro Surveill. 2009;14(30):pii=19280. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19280


Back to Table of Contents
Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.